Roche confirms 2026 outlook as Roche Holding stock trades at EUR 427.53

Published on 10/27/2026 at 10:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roche's nine-month sales rose 6 percent at constant exchange rates. Roche Holding stock trades at EUR 427.53 on October 27, 2026, with outlook intact.

Sales and pipeline metrics

Roche reported CHF 46.5 billion in nine-month 2026 sales on October 22, 2026.
Pharmaceuticals generated CHF 36.2 billion with 7 percent constant-exchange-rate growth in the first nine months.
Roche Holding stock trades at EUR 427.53 at 10:35 a.m. CET at Lang & Schwarz on October 27, 2026.

Roche Holding, CH1499059983, Illustration mit AI erstellt.

Roche Holding stock (ISIN CH1499059983) was trading at EUR 427.53 at Lang & Schwarz on October 27, 2026 at 10:35 a.m. CET. Roche confirmed its 2026 outlook after reporting nine-month sales growth of 6 percent at constant exchange rates on October 22, 2026, according to Roche.

Sales reached CHF 46.5 billion

Roche reported group sales of CHF 46.493 billion for the first nine months of 2026, versus CHF 45.862 billion a year earlier. The increase was 6 percent at constant exchange rates but 1 percent in Swiss francs, showing how currency effects shaped the headline result.

The Pharmaceuticals Division remained the main growth engine. Its sales reached CHF 36.212 billion, up 7 percent at constant exchange rates from CHF 35.555 billion in the same period of 2025, while Diagnostics sales were CHF 10.281 billion, up 4 percent at constant exchange rates from CHF 10.307 billion, according to Roche.

What does the sales mix mean?

The growth is concentrated in medicines. Roche said its five leading growth drivers generated CHF 16.8 billion in the first nine months, up 12 percent at constant exchange rates, while products with expired patents declined by CHF 0.6 billion in Swiss francs.

The counterweight is visible in Xolair. Third-quarter sales reached CHF 848 million against a Jefferies estimate of CHF 972 million, according to BioPharma Dive. Roche nevertheless kept its 2026 targets for mid-single-digit group sales growth and high-single-digit core earnings per share growth at constant exchange rates.

Three dated Roche developments

On September 23, 2026, Roche proposed Christophe Weber for election to its board at the 2027 annual meeting. On October 16, 2026, the US Food and Drug Administration approved Enspryng for thyroid eye disease. On October 22, 2026, Roche reported CHF 46.493 billion in nine-month sales and confirmed its full-year outlook, according to Roche.

Upcoming regulatory dates

Roche's giredestrant program has two scheduled FDA decision dates: November 30, 2026, for early-stage breast cancer, and December 18, 2026, for advanced disease. Both dates were listed in the October 22, 2026 Roche update.

Stock trades at EUR 427.53

The current price puts the market focus on whether Roche can turn pipeline progress into durable growth as older products face competition. The next two scheduled regulatory dates provide concrete milestones for that debate.

Roche Holding stock was trading at EUR 427.53 at Lang & Schwarz on October 27, 2026 at 10:35 a.m. CET.

The further course of trading is shown by the continuously updated real-time quote of Roche Holding stock.